Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Remitch OD Tablets Earns Indonesia Approval: Toray/Meiji Pharma
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
- Nobelpharma Takes Nobelzin Patent Fight to IP High Court
September 27, 2024
- Santen Files Glaucoma Drug Sepetaprost in Japan
September 27, 2024
- Meiji’s COVID Jab Might Miss Initial Plan, but Awaits Real Game Next Year
September 26, 2024
- J&J to Offer Rybrevant for Free until NHI Price Listing
September 26, 2024
- Daiichi Sankyo’s TROP2 ADC Misses OS Goal in Breast Cancer Trial
September 25, 2024
- No Major Physical Damages Seen with Wholesalers after Noto Downpours
September 25, 2024
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- Kissei Takes Over Marizev Marketing Authorization from MSD Japan
September 25, 2024
- Daiichi Sankyo Releases JN.1-Tailored COVID Jab Daichirona
September 25, 2024
- Astellas’ Gastric Cancer Drug Vyloy Wins European Approval
September 25, 2024
- Otsuka Wraps Up Buyout of Jnana Therapeutics
September 25, 2024
- NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable
September 24, 2024
- Japan’s 1st CGP Assay for Blood Cancer Approved: Otsuka
September 24, 2024
- Tsumura to Cover Return Costs for China Staff after Shenzhen Stabbing
September 24, 2024
- 3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
September 20, 2024
- Xofluza Cuts Risk of Flu Transmission in Households: PIII Data
September 20, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…